De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes

Saved in:
Bibliographic Details
Published in:British journal of haematology 2020-06, Vol.189 (6), p.e237-e240
Main Authors: Killick, Sally, Jackson, Aimee, Coulthard, Helen C., Yap, Christina, Das‐Gupta, Emma, Pennell, Dudley J., Porter, John, Bowen, David, Culligan, Dominic
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Blood Transfusion
Deferasirox - administration & dosage
Deferasirox - adverse effects
Disease-Free Survival
Female
Hematology
Humans
Iron
Male
Middle Aged
Myelodysplastic syndrome
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - therapy
Prospective Studies
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16669